Prodotti Clavis
( Articolo in Inglese ) <br>Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.

( Articolo in Inglese )
Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.



RESULTS: Compared with placebo, melatonin significantly advanced mean sleep onset time by 34 min, decreased mean sleep latency by 29 min, increased mean total sleep time by 48 min, reduced the mean number of times the person awoke during the night by 0.4, decreased the mean duration of these night waking periods by 17 min and advanced endogenous melatonin onset at night by an average of 2.01 h. Lights off time, sleep offset time and the number of nights per week with night waking did not change.

Fonte: http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0964-2633&date=2008&volume=52&issue=Pt%203&spage=256

 



Share |

Melatonina.it sito internet di proprieta di Clavis srl - Realizzato da InternetSol - Versione multilingue del sito Key Melatonin
Altri prodotti Clavis: Garum Sociorum Exquisitus e Magnesio - Key Alghe - Chitosano Vegetale - Pagine di Melatonina su Facebook

CLAVIS SRL - Via Della Piazza 7/D - 25127 Brescia ( BS )
C.F./P.IVA/Reg. Impr. Brescia: 02391310980 - REA 445872 - Capitale Sociale Euro 12.000,00
Tel./Fax 0303702608 - Email: info@clavis2000.com - PEC: clavis@pecservice.it